FORMULATION AND EVALUATION OF NOVEL CHROMENE DERIVATIVE AS AN ANTI INFLAMMATORY AGENT USED FOR IBD

  • Vidya Viswanad

Abstract

Objective: To formulate and evaluate an extended-release (ER) tablet of a new molecule, 2-amino-4-(4-bromophenyl)-7-hydroxy-4H-chromene-3- carbonitrile using a combination of two polymers (hydroxypropyl methyl cellulose [HPMC] K100 and HPMC phthalate) which control the rate and degree of the drug release through 12 hrs period and protect the drug release from acidic pH.

Methods: Five batches of tablets (4HC1, 4HC2, 4HC3, 4HC4, 4HC5) were produced by direct compression method. Morphological evaluation of the powder blend was carried out by differential scanning calorimetry and Powered X-ray diffractometry. The evaluation studies such as flow properties, hardness, friability, drug content, and release study were conducted according to pharmacopoeial standards.

Results: The physicochemical characteristics of all the granules and tablets were generally satisfactory. The drug release followed zero order, Higuchi model kinetics with diffusion and dissolution mediated mechanism. Tablets were evaluated for physicochemical parameters and promising. Stability studies indicated the dosage form is stable for 3 months at accelerated conditions.

Conclusion: From the results received from all test, it was concluded that formulation 4HC4 are the most suitable choice for developing 12 hrs ER

tablets. This finding reveals that a particular concentration of HPMC K100 was capable of producing ER.

Keywords: Chromene derivative, Extended-release, Hydroxypropyl methylcellulose phthalate, Hydroxypropyl methylcellulose K100.

References

1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474(7351):307-17.
2. Chandel S, Prakash A, Medhi B. Current scenario in inflammatory bowel disease: Drug development prospects. Pharmacol Rep
2015;67(2):224-9.
3. Lautenschläger C, Schmidt C, Fischer D, Stallmach A. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev 2014;71:58-76.
4. Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs.
Expert Opin Drug Deliv 2007;4(4):403-16.
5. Kaur J, Aggarwal G, Singh G, Rana AC. Improvement of drug solubility using solid dispersion. Int J Pharm Pharm Sci 2012;4(2):47-53.
6. Uddin MR, Rashid MM, Alam MR. In vitro evaluation of oral extended

release drug delivery system for trimetazidine dihydrochloride using methocel polymers. Int J Pharm Pharm Sci 2013;5(4):329-39.
7. Nanjwade BK, Mhase SR, Manvi FV. Formulation of extended- release metformin hydrochloride matrix tablets. Trop J Pharm Res
2011;10(4):375-83.
8. Thomas NA, Zachariah SM. Pharmacological activities of chromene derivatives: An overview. Asian J Pharm Clin Res 2013;6(2):11-5.
9. Keerthy HK, Mohan CD, Sivaraman Siveen K, Fuchs JE, Rangappa S, Sundaram MS, et al. Novel synthetic biscoumarins target tumor necrosis factor-a in hepatocellular carcinoma in vitro and in vivo. J Biol Chem 2014;289(46):31879-90.
10. Shah NK, Shah NM, Patel MP, Patel RG. Synthesis of 2-amino-
4H-chromene derivatives under microwave irradiation and their antimicrobial activity. J Chem Sci 2013;125(3):525-30.
11. Zachariah SM, Reshmi KP, Viswanad V, Nithya PS, Beegum FS, Rajan VK. In silico design, synthesis and in vitro studies of some novel
4-phenyl-4hchromene derivatives as antioxidant and anti-inflammatory agents. J Chem Pharm Res 2015;7(7):32-40.
12. Nitin K, Sushil K, Himanshu G, Sharma P. 3-hydroxy-2-(substituted phenyl)-4H-chromene-4-one derivatives-synthesis, spectral characterization and pharmacological screening. WRJB 2012;1(1):1-5.
13. Thumar NJ, Patel MP. Synthesis, characterization, and in vitro microbial evaluation of some new 4H-chromene and quinoline derivatives of
1H-pyrazole. J Heterocycl Chem 2012;49(5):1169-78.
14. Packiaraj JM, Venkateswaran CS, Janankiraman K. Formulation and evaluation of extended-release tablets of albuterol sulphate. Indo Am J Pharm Res 2013;3(12):1298-321.
15. Fiona P, Marina L, Ali RS. Investigation of a directly compressible metformin HCl 500 mg extended release formulation based on hypromellose. J Young Pharm 2012;4(4):220-97.
Statistics
381 Views | 212 Downloads
Citatons
How to Cite
Viswanad, V. “FORMULATION AND EVALUATION OF NOVEL CHROMENE DERIVATIVE AS AN ANTI INFLAMMATORY AGENT USED FOR IBD”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 2, Feb. 2017, pp. 319-24, doi:10.22159/ajpcr.2017.v10i2.15696.
Section
Original Article(s)